Pancreatic cancer is an increasingly lethal cancer and is often diagnosed at an advanced stage. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignant tumors and is known as the "king of cancers". The degree of malignancy is very high, making diagnosis and treatment difficult. This is because pancreatic ductal adenocarcinoma tissue contains a large amount of fibrous tissue in addition to ductal epithelial cell components. The existence of fibrous tissue results in poor blood supply for pancreatic cancer, making it difficult for chemotherapy drugs to enter, so the treatment effect is not ideal. So there is a need to develop new and more effective treatments to cure this disease.
Pancreatic Cancer Antibodies We Offer
Antibodies can be used to target cancer cells and prevent tumor growth and progression. Antibodies have been widely used in malignant tumor research, such as pancreatic cancer, breast cancer, colon cancer, non-small cell lung cancer, etc. Clinical studies have shown that antibody therapy can not only effectively kill focus cells, but also activate the human immune system to improve the body's defense against cancer, while reducing treatment side effects and improving patient survival rates. The essence of antibody therapy is to use specific monoclonal antibodies synthesized in vitro to achieve the purpose of treatment by identifying, binding and eliminating disease-related antigens or disease cells expressing antigens. Alfa Cytology has extensive experience in pancreatic cancer research and can provide you with antibody products suitable for your research project.
Alfa Cytology is committed to providing customers with antibody products with strong targeting, high stability, and obvious effects for pancreatic cancer research. We can recommend the best antibody options based on our customers' needs. If you are interested in our products, please contact us for more details.
Sophoridine
Catalog No.: PC0102
Description: Sophoridine is a quinolizidine alkaloid isolated from the leguminous plant Sophora flavescens and induces apoptosis. Sophoridine has the potential to become a new, effective, and selective anti-tumor drug candidate for pancreatic cancer with good toxicity tolerance.
LP-184
Catalog No.: PC0103
Description: LP-184 is an acylfulvene analog that inhibits tumor growth and has potent anticancer activity in ovarian, colon, prostate and pancreatic cell lines.
MKT-077
Catalog No.: PC0104
Description: MKT-077 is a highly water-soluble mitochondrial dye with significant anti-tumor activity, exhibits low cytotoxicity, and inhibits a broad spectrum of human cancer cell lines (colon cancer, breast cancer, pancreatic cancer).
Rineterkib
Catalog No.: PC0105
Description: Rineterkib is an oral ERK1 and ERK2 inhibitor indicated for the treatment of proliferative diseases characterized by activating mutations in the MAPK pathway. This activity is particularly relevant for the treatment of KRAS -mutant NSCLC, BRAF -mutant NSCLC, KRAS -mutant pancreatic cancer, KRAS -mutant colorectal cancer (CRC), and KRAS -mutant ovarian cancer.
Rineterkib hydrochloride
Catalog No.: PC0106
Description: Rineterkib Hydrochronide is an oral ERK1 and ERK2 inhibitor indicated for the treatment of proliferative diseases characterized by activating mutations in the MAPK pathway. This activity is particularly relevant for the treatment of KRAS -mutant NSCLC, BRAF -mutant NSCLC, KRAS -mutant pancreatic cancer, KRAS -mutant colorectal cancer (CRC), and KRAS -mutant ovarian cancer.
Mycro 3
Catalog No.: PC0107
Description: Mycro 3 is an orally active, potent, and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibits DNA binding of c-Myc and can be used in pancreatic cancer research.
(Rac)-GSK547
Catalog No.: PC0108
Description: (Rac)-GSK547, the racemate of GSK547, is a highly selective and potent receptor-interacting RIP1 inhibitor that inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer.
S100P-IN-1
Catalog No.: PC0109
Description: S100P-IN-1 is an S100P inhibitor with an IC50 of 22.7 nM and has an anti-metastatic effect on pancreatic cancer cells.
GAC0003A4
Catalog No.: PC0110
Description: GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity and also efficiently degrades LXRβ protein. GAC0003A4 has the potential to treat advanced pancreatic cancer and other refractory malignancies.
Antiproliferative agent-45
Catalog No.: PC0111
Description: Antiproliferative agent-45 is a prodrug. Antiproliferative agent-45 exhibits significant antiproliferative effects on human pancreatic cells under hypoxic conditions, but is less effective under normoxic conditions. Antiproliferative agent-45 may be used in cancer research.
Sulforaphane
Catalog No.: PC0112
Description: Sulforaphane is an isothiocyanate present naturally in widely consumed vegetables. Sulforaphane increases tumor suppressor protein transcription and inhibits histone deacetylase activity. Sulforaphane activates Nrf2 and inhibits high glucose-induced progression of pancreatic cancer via AMPK dependent signaling. Sulforaphane has shown anti-cancer and anti-inflammatory activities.
Alovudine
Catalog No.: PC0113
Description: Alovudine (3'-Fluoro-3'-deoxythymidine) is a marker of DNA synthesis that is less susceptible to inflammatory changes than 18F-Fluorodeoxyglucose (FDG) and thus is a better biomarker in pancreatic cancer.
Vantictumab
Catalog No.: PC0114
Description: Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody that inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. It can be studied to treat cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic cancer.
MAT2A-IN-5
Catalog No.: PC0115
Description: MAT2A-IN-5 is a potent inhibitor of MAT2A, and its expression levels are abnormally elevated in several types of tumors, including gastric, colon, liver, and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells.
MAT2A-IN-6
Catalog No.: PC0116
Description: MAT2A-IN-6 is a potent inhibitor of MAT2A. Expression levels of MAT2A are abnormally elevated in several types of tumors, including gastric, colon, liver, and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells.
MAT2A-IN-7
Catalog No.: PC0117
Description: MAT2A-IN-7 is a potent inhibitor of MAT2A. Expression levels of MAT2A are abnormally elevated in several types of tumors, including gastric, colon, liver, and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells.
MAT2A-IN-3
Catalog No.: PC0118
Description: MAT2A-IN-3 is a potent inhibitor of MAT2A. Expression levels of MAT2A are abnormally high in several types of tumors, including gastric, colon, liver, and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells.
MAT2A-IN-2
Catalog No.: PC0119
Description: MAT2A-IN-2 is a potent inhibitor of MAT2A. Expression levels of MAT2A are abnormally high in several types of tumors, including gastric, colon, liver, and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells.
MAT2A-IN-1
Catalog No.: PC0120
Description: MAT2A-IN-1 is a potent inhibitor of MAT2A. Expression levels of MAT2A are abnormally high in several types of tumors, including gastric, colon, liver, and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells.
Carbidopa-d3 monohydrate
Catalog No.: PC0121
Description: Carbidopa-d3 (monohydrate) is deuterium-labeled carbidopa monohydrate, a peripheral decarboxylase inhibitor that can be used in the study of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cells and tumor growth.